All articles by Annabel Kartal Allen

Annabel Kartal Allen

Annabel Kartal-Allen is a reporter for Clinical Trials Arena, Pharmaceutical Technology and Medical Device Network based in London, UK. Annabel holds interests in oncology, neurology and metabolic diseases. She has previous experience reporting for both the pharmaceutical and nutraceutical industries, and holds a BSc in Biology from the University of Sussex. Contact Annabel

Protara’s cell therapy touts BCG-naïve treatment potential in Phase II

Protara’s lead candidate, TARA-002, has demonstrated durable complete response (CR) rates in a single-arm Phase II trial in Bacillus Calmette-Guérin…
FDA appoints Tracy Beth Høeg as fifth CDER head this year

The US Food and Drug Administration (FDA) has selected Tracy Beth Høeg as its new head of drug research and…
Imvax to explore FDA pathway for glioblastoma candidate despite PFS miss

Imvax is preparing for discussions with US regulators about the next steps for IGV-001 in newly diagnosed glioblastoma (ndGBM) despite…
Richard Padzur to leave FDA following recent CDER leadership shift

After less than a month in his new role as head of the US Food and Drug Administration’s (FDA) Center…
OCT DACH 2025: Geopolitics, trial equity and technology take centre stage

At Arena International’s Outsourcing in Clinical Trials (OCT) DACH 2025 conference, technology took centre stage, with emerging and established tools…

FDA steps back from preclinical primate testing amid wider regulatory shift

The US Food and Drug Administration (FDA) has taken another step away from animal testing – this time through draft…
Belite eyes tinlarebant approval after late-stage Stargardt success

Belite Bio is seeking US approval of its lead ophthalmology asset, tinlarebant, in Stargardt disease 1 (STGD1) following the positive…
Jacobio’s NSCLC combo touts 71% ORR in Phase I/IIa trial

Jacobio Pharma’s oncology combination of glecirasib and sitneprotafib has shown promise during an early-stage trial as a first-line treatment for…
Renalys eyes Japanese Filspari approval on Phase III IgA nephropathy win

Renalys Pharma is vying for the approval of its in-licensed immunoglobulin A (IgA) nephropathy asset, Filspari (sparsentan) in Japan, following…
Novo Nordisk to advance amylin agonist to Phase III in type 2 diabetes

Novo Nordisk is advancing its amylin agonist, amycretin, to Phase III in type 2 diabetes (T2D) after the drug met…